Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory

Breast Cancer Research and Treatment

Volumn 89, Issue 2, 2005, Pages 187-197

  Miller, Kathy D ^a,b   Soule, Sharon E ^a   Calley, Cynthia ^a   Emerson, Robert E ^a   Hutchins, Gary D ^a   Kopecky, Kenyon ^a   Badve, Sunil ^a   Storniolo, AnnaMaria ^a   Goulet, Robert ^a   Sledge Jr , George W ^a  

^a INDIANA UNIVERSITY   (United States)

^b RT 473 ^*  (United States)

Author keywords

Basic fibroblast growth factor (bFGF); Color Doppler ultrasound; Microvessel density; Positron emission tomography; Vascular cell adhesion molecule 1 (VCAM 1)

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CARBON 11; CARBON MONOXIDE C 11; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANGIOGENESIS; ANOREXIA; ANXIETY DISORDER; ARTICLE; AXILLARY LYMPH NODE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HUMAN; INFECTION; INFLAMMATION; INHIBITION KINETICS; LACRIMATION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROBLAST GROWTH FACTOR 2; FLUORODEOXYGLUCOSE F18; HUMANS; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 20844437405     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-2044-y     Document Type: Article

References (60)

1. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990
2. Gasparini G: Angiogenesis in breast cancer. Role in biology, tumor progression, and prognosis. In: Bowcock A, NJ Totowa, (eds) Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics, Humana Press Inc., 1999, pp 347-371
3. Miller K, Sweeney C, Sledge G: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19: 1195-1206, 2001
4. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato R.J: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 57: 81-86, 1997
5. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-1849, 1996
6. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW, Jr.: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61: 3369-3372, 2001
7. Benbow U, Maitra R, Hamilton J, Brinckerhoff C: Selective modulation of collagenase 1 gene expression by the chemotherapeutic agent doxorubicin. Clin Cancer Res 5: 203-208, 1999
8. Lorenzo E, Ruiz-Ruiz C, Quesada AJ, Hernandez G, Rodriguez A, Lopez-Rivas A, Redondo JM: Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 277: 10883-10892, 2002
9. Makris A, Powles T, Ashley S, Chang J, Hickish T, Tidy V, Nash A, Ford H: A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9: 1179-1184, 1998
10. Mauriac L, Durand M, Avril A, Dilhuydy J-M: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 2: 347-354, 1991
11. Scholl S, Fourquet A, Asselain B, Pierga J, Vilcoq J, Durand J, Dorval T, Palangie T, Jouve M, Beuzeboc P, Garcio-Giralt E, Slamon R, de la Rochefordiere A, Campana F, Pouillart P: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645-652, 1994
12. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher E, Wickerham D, Begovic M, DeCillis A, Rabidoux A, Margolese R, Cruz A, Hoehn J, Lees A, NV D, Bear H: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998
13. Scholl S, Pierga J, Asselain B, Beuzeboc P, Dorval T, Garcia-Giralt E, Jouve M, Palangie T, Remvikos Y, Durand J, Fourquet A, Pouillart P: Breast tumor response to primary chemothrapy predicts local and distant control as well as survival. Eur J Cancer 31A: 1969-1975, 1995
14. Laing K, Ragaz J, Le N, Manji M, McLarden D, Yu S, Jackson S, Olivotto I, Gelmon K: Correlation of modified radical mastectomy with outcome of stage III breast cancer patients treated with preoperative therapy: is there a need for randomized trials? Analysis of the British Columbia Study. Proc Am Soc Clin Oncol 17: 168a, 1998
15. Valagussa P, Zambetti M, Bonadonna G, Zucali R, Mezzanotte G, Veronesi, U: Prognostic factors in locally advanced noninflammatory breast cancer: Long term results following primary chemotherapy. Breast Cancer Res Treat 15: 137-147, 1990
16. Tynninen O, Sjostrom J, von Boguslawski K, Bengtsson NO, Heikkila R, Malmstrom P, Ostenstad B, Wist E, Valvere V, Saksela E, Paavonen T, Blomqvist C: Tumour microvessel density as predictor of chemotherapy response in breast cancer patients. Br J Cancer 86: 1905-1908, 2002
17. Jennison C, Turnbull B: Confidence intervals for a binomial parameter following a multistage test with application to MIL-STD 105D and medical trials. Technometrics 25: 49-58, 1983
18. Link J, Forsthoff C, Ibarra J, Rogers LW, Magy F, Maya KA: Dose-dense doxorubicin, docetaxel and cyclophosphamide as sequential neoadjuvant therapy for high-risk breast cancer: a pilot study. Breast Cancer Res Treat 82(Suppl 1): S59, 2003
19. Cooper B, Silverman P, Overmoyer B, Shenk R, Allen M: Study of dose-dense doxorubicin and docetaxel for patients with advanced operable and inoperable adenocarcinoma of the breast. Breast Cancer Res Treat 82 (Suppl 1): S57, 2003
20. Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R, Sledge GW, Jr.: Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17: 3033-3037, 1999
21. Esmaeli B, Hortobagyi G, Esteva F, Valero V, Ahmadi MA, Booser D, Ibrahim N, Delpassand E, Arbuckle R: Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 13: 218-221, 2002
22. Hidaji L, Amir Ahmadi M, Arbuckle R, Valero V, Rivera E, Newman RA, Tu S-M, Mathew P, Esmaeli B: Excessive tearing and canalicular blockage as a side effect of docetaxel. Proc Am Soc Clin Oncol 22: 12, 2003
23. Ganem G, Tubiana-Hulin M, Fumoleau P, Combe M, Misset JL, Vannetzel JM, Bachelot T, De Ybarlucea LR, Lotz V, Bendahmane B, Dieras V: Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14: 1623-1628, 2003
24. von Minckwitz G, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Gademann G, Tulusan AH, Eiermann W, Graf E, Kaufmann M: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 19: 3506-3515, 2001
25. Jackisch C, von Minckwitz G, Eidtmann H, Costa SD, Raab G, Blohmer JU, Schutte M, Gerber B, Merkle E, Gademann G, Lampe D, Hilfrich J, Tulusan AH, Caputo A, Kaufmann M: Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. Clin Breast Cancer 3: 276-280, 2002
26. Zujewski JA, Eng-Wong J, O'Shaughnessy J, Venzon D, Chow C, Danforth D, Kohler DR, Cusack G, Riseberg D, Cowan KH: A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer. Breast Cancer Res Treat 81: 41-51, 2003
27. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588-592, 2003
28. Linderholm B, Lindh B, Beckman L, Tavelin B, Grankvist K, Bergh J, Henriksson R: The prognostic value of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) and associations to first metastases site in 1307 patients with primary breast cancer. Proc Am Soc Clin Oncol 20: 4a, 2001
29. Ellenberg JH: Selection bias in observational and experimental studies. Stat Med 13: 557-567, 1994
30. Yusuf S, Wittes J, Probstfield J, Tyroler HA: Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Jama 266: 93-98, 1991
31. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, Hayes DF: A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9: 124-133, 2003
32. Untch M, Kahlert S, Moebus V, Thomssen C, Muck B, Von Bismarck F, Wallwiener D, Kreienberg, R: Negative steroid receptors are a good predictor for response to preoperative chemotherapy in breast cancer. Proc Am Soc Clin Oncol 22: 9, 2003
33. Colleoni M, Minchella I, Mazzarol G, Nole F, Peruzzotti G, Rocca A, Viale G, Orlando L, Ferretti G, Curigliano G, Veronesi P, Intra M, Goldhirsch A: Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 11: 1057-1059, 2000
34. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3: 593-600, 1997
35. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17: 3058-3063, 1999
36. Campiglio M, Somenzi G, Olgiati C, Beretta G, Balsari A, Zaffaroni N, Valagussa P, Menard S: Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer 105: 568-573, 2003
37. Colleoni M, Orvieto E, Nole F, Orlando L, Minchella I, Viale G, Peruzzotti G, Robertson C, Noberasco C, Galimberti V, Sacchini V, Veronesi P, Zurrida S, Orecchia R, Goldhirsch A: Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 35: 574-579, 1999
38. Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul J, Kaye SB, Brown R: Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 18: 87-93, 2000
39. Regitnig P, Reiner A, Dinges HP, Hofler G, Muller-Holzner E, Lax SF, Obrist P, Rudas M, Quehenberger F: Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 441: 328-334, 2002
40. Verkooijen HM, Peterse JL, Schipper ME, Buskens E, Hendriks JH, Pijnappel RM, Peeters PH, Borel Rinkes IH, Mali WP, Holland R: Interobserver variability between general and expert pathologists during the histopathological assessment of large-core needle and open biopsies of non-palpable breast lesions. Eur J Cancer 39: 2187-2191, 2003
41. Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL: HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 14: 1079-1086, 2001
42. Kedar RP, Cosgrove DO, Smith IE, Mansi JL, Bamber JC: Breast carcinoma: measurement of tumor response to primary medical therapy with color Doppler flow imaging. Radiology 190: 825-830, 1994
43. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, Werner M, Dose J, Janicke F, Graeff H, Schwaiger M: Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18: 1689-1695, 2000
44. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11: 2101-2111, 1993
45. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J: Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 13: 1470-1477, 1995
46. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ, Wong WH, Hicks KW, Buzdar AU, Podoloff DA: Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 37: 931-938, 1996
47. Mankoff D, Dunnwald L, Gralow J, Ellis GK, Drucker MJ, Livingston RB: Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using {technetium 99m}-sestamibi scintimammography. Cancer 85: 2410-2423, 1999
48. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O, Heys SD, Gilbert FJ, Sharp PF: Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18: 1676-1688, 2000
49. Peters-Engl C, Medl M, Mirau M, Wanner C, Bilgi S, Sevelda P, Obermair A: Color-coded and spectral Doppler flow in breast carcinomas - relationship with the tumor microvasculature. Breast Cancer Res Treat 47: 83-89, 1998
50. Lee WJ, Chu JS, Houng SJ, Chung MF, Wang SM, Chen KM: Breast cancer angiogenesis: a quantitative morphologic and Doppler imaging study. Ann Surg Oncol 2: 246-251, 1995
51. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF: Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20: 379-387, 2002
52. Zasadny KR, Tatsumi M, Wahl RL: FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 30: 274-280, 2003
53. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, Tseng J, Livingston RB: Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 43: 500-509, 2002
54. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, Lawton TJ, Linden HM, Livingston RB: Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 44: 1806-1814, 2003
55. Douglas-Jones AG, Collett N, Morgan JM, Jasani B: Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol 54: 951-955, 2001
56. Jacobs TW, Siziopikou KP, Prioleau JE, Raza S, Baum JK, Hayes DF, Schnitt SJ: Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Mod Pathol 11: 259-264, 1998
57. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369, 2003
58. Pusztai L, Ayers M, Simmans F, Damokosh A, Hess K, Valero V, Clark E, Ross J, Hortobagyi G, Stec J: Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc Am Soc Clin Oncol 22: Abstract 1, 2003
59. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF: Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 9: 2406-2415, 2003
60. Soule SE, Shak S, Baker J, Cronin M, Liu M-L, Badve S, Miller KD, Sledge GW: Predicting response to chemotherapy in invasive breast cancer: Gene expression profiling of paraffin-embedded core biopsy tissue. Proc Am Soc Clin Oncol 22: 862, 2003